BMAC Doesn't Work for Everyone. That's Exactly the Point, Says Franklin, TN Orthopedic Surgeon Dr. Ethan Kellum.

Nov 21, 2026

Franklin, TN, United States, November 21, 2026 -- With growing patient interest in bone marrow aspirate concentrate for joint conditions, Dr. Ethan Kellum Regenerative Solutions is addressing a question the science already answers: BMAC's value depends on who receives it, not just what it does.


Franklin, TN, November 3, 2026: Dr. Ethan Kellum, MD/MS, a fellowship-trained orthopedic surgeon and regenerative medicine specialist practicing in Franklin, Tennessee, is speaking directly to patients who've heard conflicting things about bone marrow aspirate concentrate (BMAC) and aren't sure what to believe. His position is straightforward: BMAC produces real clinical results for the right patients, and it falls short when applied without proper candidacy evaluation. That distinction isn't a marketing claim. It's a description of how orthobiologic medicine behaves in the body.


"What I want patients to understand is that BMAC not working universally isn't a weakness of the therapy," said Dr. Kellum. "It's a description of biology. The concentrate delivers growth factors, cytokines, and progenitor cells drawn from a patient's own bone marrow. What it does in the joint depends on the tissue it encounters, the severity of the condition, the patient's age and biologic profile, and the vascularity of the target structure. A partial-thickness rotator cuff tear in a 40-year-old is a different problem than advanced knee osteoarthritis in a 65-year-old, and BMAC responds to them accordingly. Treating those as equivalent candidates is where outcomes go wrong."


Why Candidacy Comes Before Treatment
Dr. Kellum has treated more than 10,000 patients since beginning practice in 2005 and established his regenerative medicine practice in Tennessee in 2017. He holds fellowship training from New England Baptist Hospital and Boston Children's Hospital, trained in orthopedic surgery at the Medical College of Georgia, and earned his medical degree from the University of Tennessee Health Science Center. He serves as team physician for the Tennessee Titans and USA Basketball and previously worked with the Boston Celtics. He is a member of the Alpha Omega Alpha medical honor society and an author of peer-reviewed medical publications.


That depth of background shapes how the practice evaluates patients. Before any treatment is recommended, Dr. Kellum conducts a thorough orthopedic assessment. The evaluation considers the specific diagnosis, how far the condition has progressed, what treatments have already been tried, and whether the patient's anatomy and biology make them a reasonable candidate for a regenerative approach. Surgery stays on the table throughout that conversation. Dr. Kellum continues to perform arthroscopic procedures of the shoulder and knee. The model is built around finding the right answer, not defaulting to any single path.


Consider a patient who comes in after months of knee pain, having been told surgery is likely the next step. Depending on the presentation, a candidacy evaluation might confirm that. It might also identify a condition that responds well to BMAC or PRP, or one that benefits from surgery combined with orthobiologics. The consultation exists to sort through those possibilities with clinical precision. What it doesn't do is start with a predetermined recommendation and work backward.


What BMAC Actually Does in the Joint
BMAC is drawn from the patient's own bone marrow, typically from the iliac crest. The concentrate is processed to increase the density of growth factors, cytokines, and progenitor cells, then injected into the target area. In tissue with adequate vascularity and a condition that hasn't progressed beyond a point of reasonable biological response, those biologics modulate inflammation and support local repair processes. That mechanism is real, documented, and clinically meaningful in appropriate candidates.


It's also not universal. Grade IV cartilage loss, advanced joint destruction, or conditions with compromised local blood supply present a different biological environment. BMAC interacts with that environment differently, and honest evaluation has to account for it. Patients who've been told BMAC is a blanket surgery replacement deserve to know the clinical picture is more specific than that. Patients who've been told surgery is their only option deserve to know that for certain diagnoses, a well-indicated BMAC procedure has genuine clinical support behind it.


The practice also offers PRP, adipose-derived treatments, prolotherapy, and other orthobiologics. Dr. Kellum is among the early adopters of advanced regenerative treatments in Tennessee and is currently expanding treatment capabilities with Dezawa Muse Cell therapy.


Who Should Have This Conversation
Patients throughout Nashville, Franklin, Brentwood, and Cool Springs exploring BMAC for knee pain, hip or shoulder degeneration, a sports injury, a spinal condition, or chronic joint problems have access to the kind of evaluation that actually determines whether the therapy fits their situation. Patients also travel from across Tennessee and from other states to consult with Dr. Kellum specifically because of his combined background in orthopedic surgery and regenerative medicine.


Waiting to explore options isn't a neutral choice. Joint conditions don't tend to simplify over time, and some biological windows for regenerative treatment narrow as degeneration progresses. A consultation at Dr. Ethan Kellum Regenerative Solutions doesn't commit anyone to a procedure. It's the beginning of an informed conversation about what's actually happening in the joint and what the realistic options are for that specific patient.


About Dr. Ethan Kellum Regenerative Solutions
Dr. Ethan Kellum Regenerative Solutions is a fellowship-trained orthopedic and regenerative medicine practice based in Franklin, Tennessee, serving patients throughout the Nashville, Brentwood, and Cool Springs areas. Founded in 2017 by Dr. Ethan Kellum, MD/MS, the practice helps patients with joint pain, arthritis, and orthopedic injuries evaluate the full range of treatment options, including BMAC, PRP, orthobiologics, and surgery when clinically indicated. Dr. Kellum serves as team physician for the Tennessee Titans and USA Basketball, holds fellowship training from New England Baptist Hospital and Boston Children's Hospital, and is a member of the Alpha Omega Alpha medical honor society.

Contact Info:
Name: Dr. Ethan Kellum
Email: Send Email
Organization: Dr. Ethan Kellum Regenerative Solutions
Phone: +1 615 850 4415
Website: https://drethankellum.com

Release ID: 89210396

If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.

More News

Marcos Jnr promised a ‘new Philippines’. What happened?
Nov 21, 2026
Marcos Jnr promised a ‘new Philippines’. What happened?

“I knew your parents very well and they were great,” US President Donald Trump told his Philippine counterpart at a dinner in Manila this week, offering a glowing tribute to a family that was once forced into exile in disgrace. Turning to his host, Ferdinand “Bongbong” Marcos Jnr, Trump recalled his friendship with the Philippine leader’s parents, the late dictator Ferdinand Marcos Snr and his wife Imelda. “It’s a true pleasure to be back in the Philippines. I’ve been here numerous times,” he...

Trump Flaunts Camaraderie With Xi and Putin but Has Little to Show for It
Nov 20, 2026
Trump Flaunts Camaraderie With Xi and Putin but Has Little to Show for It

President Trump called Russia’s leader his “friend” and marveled at China’s warm welcome for his first-ever trilateral summit. But there were no breakthroughs on nuclear control, the war in Ukraine or A.I.

Chinese-Born Neuroscientist Is Detained by ICE While Traveling From Conference
Nov 20, 2026
Chinese-Born Neuroscientist Is Detained by ICE While Traveling From Conference

Eva Yi Xie was detained on her way back to New Jersey from a neuroscience conference in Washington this week, the latest in a string of researcher arrests.

Nissan Shuts Down System Used for Repairs After Hack Attempt
Nov 20, 2026
Nissan Shuts Down System Used for Repairs After Hack Attempt

The outage, which began a week ago, could delay repairs involving vehicle electronics and key fobs.

Indian man jailed over US murder plot against Sikh separatist
Nov 20, 2026
Indian man jailed over US murder plot against Sikh separatist

An Indian man was sentenced to more than 19 years in US prison on Friday after admitting to orchestrating a failed Indian government-backed plot to ‌kill a Sikh separatist in New York, in connection with what US and Canadian authorities have called a broader effort to target Indian dissidents. Nikhil Gupta, 55, pleaded guilty in February to murder-for-hire, conspiracy to commit murder-for-hire and conspiracy to commit money laundering. US District Judge Victor Marrero handed down the 235-month...

Alice Huang, Accused of Spying on Nvidia’s CEO, Is Linked to Firms With Ties to China’s Military
Nov 20, 2026
Alice Huang, Accused of Spying on Nvidia’s CEO, Is Linked to Firms With Ties to China’s Military

Companies linked to Alice Huang, the woman at the heart of the Nvidia scandal, are part of a network of Chinese tech firms and defense contractors that need advanced computing power.

At APEC Summit, U.S., China and Russia Vow to Increase Oil Supply Amid Global Energy Transition
Nov 20, 2026
At APEC Summit, U.S., China and Russia Vow to Increase Oil Supply Amid Global Energy Transition

The United States, China and Russia agreed to boost the supply of refined petroleum products, as oil prices spike because of the Iran war.

China Is Investing in Africa’s Factory Moment. Will It Stay?
Nov 20, 2026
China Is Investing in Africa’s Factory Moment. Will It Stay?

Chinese companies are increasing investments in African manufacturing and processing. Will they also buy from local suppliers and train local engineers?

Uzbekistan’s Energy Sector Faces the Perfect Storm 
Nov 20, 2026
Uzbekistan’s Energy Sector Faces the Perfect Storm 

They way forward requires immense investment. But international investors need legal certainty and protection from political interference.

ICJ’s Genocide Verdict on Myanmar and the Ramifications for Israel
Nov 20, 2026
ICJ’s Genocide Verdict on Myanmar and the Ramifications for Israel

Legal experts warn of a potential backlash against the ICJ after its Rohingya ruling.

China’s Downstream Nations Need a Collective Voice
Nov 20, 2026
China’s Downstream Nations Need a Collective Voice

Across Asia’s river basins, upper-riparian infrastructure proceeds unilaterally, without consultation to downstream states. China’s mega-dam in Tibet is just the latest example.

Putin Exits Summit With Symbolic Win, Saying He and Trump Share ‘Values’
Nov 20, 2026
Putin Exits Summit With Symbolic Win, Saying He and Trump Share ‘Values’

Standing alongside the U.S. and Chinese leaders, President Vladimir V. Putin secured a symbolic triumph in his long quest to restore Russia’s place as a global power.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Indo Inquirer

Indo Inquirer is the leading online news network in Indonesia, providing daily breaking news with in-depth news coverage and the best photojournalism. We deliver compelling and diverse engaging stories around the world.

Newsletter